Sigma Planning Corp Cuts Stake in Liquidia Co. (NASDAQ:LQDA)

Sigma Planning Corp lessened its holdings in shares of Liquidia Co. (NASDAQ:LQDA) by 58.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 39,635 shares of the company’s stock after selling 56,005 shares during the period. Sigma Planning Corp owned approximately 0.06% of Liquidia worth $477,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in LQDA. Greenleaf Trust purchased a new stake in Liquidia in the fourth quarter valued at about $164,000. Simplicity Solutions LLC boosted its stake in Liquidia by 45.6% in the 4th quarter. Simplicity Solutions LLC now owns 31,193 shares of the company’s stock worth $375,000 after purchasing an additional 9,764 shares in the last quarter. Cerity Partners LLC purchased a new stake in Liquidia during the 4th quarter worth approximately $197,000. LB Partners LLC acquired a new position in Liquidia during the 4th quarter valued at approximately $3,404,000. Finally, Bleakley Financial Group LLC raised its holdings in shares of Liquidia by 45.6% in the fourth quarter. Bleakley Financial Group LLC now owns 31,193 shares of the company’s stock worth $375,000 after buying an additional 9,764 shares during the last quarter. Institutional investors and hedge funds own 64.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on LQDA shares. Needham & Company LLC reissued a “buy” rating and issued a $28.00 target price on shares of Liquidia in a research report on Wednesday, April 10th. HC Wainwright increased their price objective on Liquidia from $16.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, March 14th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. According to MarketBeat, Liquidia has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Liquidia Stock Performance

NASDAQ LQDA opened at $12.37 on Friday. The firm has a market capitalization of $940.49 million, a P/E ratio of -10.31 and a beta of 0.16. The stock has a 50-day simple moving average of $14.55 and a two-hundred day simple moving average of $11.19. Liquidia Co. has a fifty-two week low of $5.71 and a fifty-two week high of $16.99.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Wednesday, March 13th. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.19). Liquidia had a negative net margin of 448.89% and a negative return on equity of 132.16%. The company had revenue of $4.53 million for the quarter, compared to analysts’ expectations of $5.29 million. As a group, analysts forecast that Liquidia Co. will post -1.01 earnings per share for the current year.

Insider Activity at Liquidia

In related news, General Counsel Russell Schundler sold 8,653 shares of the firm’s stock in a transaction on Monday, March 18th. The shares were sold at an average price of $15.82, for a total transaction of $136,890.46. Following the sale, the general counsel now owns 488,087 shares in the company, valued at $7,721,536.34. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, General Counsel Russell Schundler sold 8,653 shares of the stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $15.82, for a total transaction of $136,890.46. Following the sale, the general counsel now directly owns 488,087 shares of the company’s stock, valued at approximately $7,721,536.34. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Jason Adair sold 4,657 shares of Liquidia stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $15.81, for a total value of $73,627.17. Following the completion of the transaction, the insider now owns 108,640 shares of the company’s stock, valued at approximately $1,717,598.40. The disclosure for this sale can be found here. Insiders sold a total of 70,999 shares of company stock worth $1,100,444 in the last three months. Company insiders own 31.60% of the company’s stock.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).